eBC and mBC Treatment | KISQALI® (ribociclib) Learn about KISQALI, a treatment option for HER+, HER2- early breast cancer (eBC) and metastatic breast cancer (mBC) See full Prescribing and Safety Info
Metastatic Breast Cancer | KISQALI® (ribociclib) Learn about HR+, HER2- metastatic breast cancer treatment in premenopausal and postmenopausal women with KISQALI See full Prescribing Safety Info
How KISQALI® (ribociclib) Works | mBC Learn how KISQALI can work as a possible HR+, HER2- metastatic breast cancer treatment combined with hormone therapy See full Prescribing Safety Info
Novartis Patient Support | KISQALI Learn more about Novartis Patient Support for KISQALI® (ribociclib) and access available financial support resources See full Prescribing and Safety Info
How to Take KISQALI for eBC | KISQALI® (ribociclib) Learn more about the dosing and how to take KISQALI for early breast cancer (eBC) in combination with an aromatase inhibitor See full Prescribing and Safety Info
Side Effects | mBC | KISQALI® (ribociclib) Read about the common and serious side effects you may experience while taking KISQALI and learn how to manage them See full Prescribing Safety Info